Crohn’s disease

Burrill Bernard Crohn was an American gastroenterologist renowned for his pivotal role in identifying the chronic ...

AUGUST 14, 2025

A large study of biologics de-escalation in patients with CD shows that the practice is common and apparently ...

APRIL 7, 2025

Researchers have developed an integrative risk score that can predict the risk of developing CD in people with a ...

DECEMBER 26, 2024

The market dominance of Humira may finally be at an end, as payors make dramatic shifts in favor of biosimilars to ...

DECEMBER 12, 2024

Miguel Regueiro, MD, sat down with GEN to talk about some of his favorite studies focused on treating IBD.

NOVEMBER 19, 2024

Many patients with IBD experience IBS–type symptoms, and clinicians can have a difficult time teasing out the ...

NOVEMBER 12, 2024

Imbalances in the gut microbiome can have negative health consequences, but the jury is still out on how to best ...

NOVEMBER 4, 2024

The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...

OCTOBER 13, 2024

The FDA has approved ustekinumab-aauz (Otulfi, Fresenius Kabi/Formycon), a biosimilar to ustekinumab (Stelara, ...

OCTOBER 7, 2024

Focusing on the mental well-being of patients with Crohn’s disease is likely to help them achieve sustained ...

OCTOBER 7, 2024

The development of effective biologics and small molecule targeted therapies has revolutionized the treatment of ...

SEPTEMBER 5, 2024

In this installment of Expert Picks from DDW 2024, Anisa Shaker, MD, discusses five of her favorite abstracts and ...

JULY 12, 2024